James E Bradner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3697203/publications.pdf

Version: 2024-02-01

211 papers	40,251 citations	3525 90 h-index	2825 191 g-index
219 all docs	219 docs citations	219 times ranked	43398 citing authors

#	Article	IF	Citations
1	Selective inhibition of BET bromodomains. Nature, 2010, 468, 1067-1073.	13.7	3,456
2	BET Bromodomain Inhibition asÂa Therapeutic Strategy to Target c-Myc. Cell, 2011, 146, 904-917.	13.5	2,432
3	Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers. Cell, 2013, 153, 320-334.	13.5	2,366
4	RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature, 2011, 478, 524-528.	13.7	1,656
5	Transcriptional Amplification in Tumor Cells with Elevated c-Myc. Cell, 2012, 151, 56-67.	13.5	1,262
6	Phthalimide conjugation as a strategy for in vivo target protein degradation. Science, 2015, 348, 1376-1381.	6.0	1,244
7	The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. Science, 2014, 343, 305-309.	6.0	1,196
8	Transcriptional Addiction in Cancer. Cell, 2017, 168, 629-643.	13.5	843
9	R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. Cell, 2018, 172, 90-105.e23.	13.5	794
10	YY1 Is a Structural Regulator of Enhancer-Promoter Loops. Cell, 2017, 171, 1573-1588.e28.	13.5	749
11	Chemical phylogenetics of histone deacetylases. Nature Chemical Biology, 2010, 6, 238-243.	3.9	646
12	Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma. Cancer Cell, 2013, 24, 777-790.	7.7	635
13	The dTAG system for immediate and target-specific protein degradation. Nature Chemical Biology, 2018, 14, 431-441.	3.9	629
14	Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discovery, 2015, 5, 1210-1223.	7.7	575
15	A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia. Cell, 2014, 157, 369-381.	13.5	571
16	Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discovery, 2013, 3, 308-323.	7.7	549
17	NF-Î²B Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis. Molecular Cell, 2014, 56, 219-231.	4.5	507
18	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature, 2016, 529, 413-417.	13.7	490

#	Article	IF	Citations
19	Quantitative ChIP-Seq Normalization Reveals Global Modulation of the Epigenome. Cell Reports, 2014, 9, 1163-1170.	2.9	442
20	Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. Cell, 2016, 164, 293-309.	13.5	399
21	MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science, 2016, 351, 1214-1218.	6.0	396
22	Plasticity in binding confers selectivity in ligand-induced protein degradation. Nature Chemical Biology, 2018, 14, 706-714.	3.9	391
23	PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature, 2014, 514, 247-251.	13.7	386
24	Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers. Molecular Cell, 2015, 58, 362-370.	4.5	382
25	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. Cancer Cell, 2014, 26, 909-922.	7.7	376
26	Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nature Chemical Biology, 2018, 14, 163-170.	3.9	376
27	RNA Exosome-Regulated Long Non-Coding RNA Transcription Controls Super-Enhancer Activity. Cell, 2015, 161, 774-789.	13.5	370
28	Small-Molecule Inhibition of BRDT for Male Contraception. Cell, 2012, 150, 673-684.	13.5	353
29	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine, 2015, 21, 1163-1171.	15.2	349
30	BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. Molecular Cell, 2017, 67, 5-18.e19.	4.5	347
31	BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure. Cell, 2013, 154, 569-582.	13.5	346
32	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nature Genetics, 2014, 46, 364-370.	9.4	333
33	BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Reports, 2016, 16, 2829-2837.	2.9	331
34	BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood, 2012, 120, 2843-2852.	0.6	329
35	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature, 2016, 530, 57-62.	13.7	318
36	A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. Cell Chemical Biology, 2018, 25, 88-99.e6.	2.5	313

#	Article	IF	Citations
37	BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma. Clinical Cancer Research, 2014, 20, 912-925.	3.2	296
38	The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature, 2013, 498, 246-250.	13.7	278
39	MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 652-665.	7.7	274
40	A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. Nature Cell Biology, 2018, 20, 1410-1420.	4.6	265
41	Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nature Medicine, 2014, 20, 732-740.	15.2	255
42	Transcription control by the ENL YEATS domain in acute leukaemia. Nature, 2017, 543, 270-274.	13.7	248
43	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Reports, 2017, 18, 2162-2174.	2.9	244
44	Prostate cancerâ€“associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature Medicine, 2017, 23, 1063-1071.	15.2	240
45	Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nature Biotechnology, 2015, 33, 415-423.	9.4	237
46	Models of human core transcriptional regulatory circuitries. Genome Research, 2016, 26, 385-396.	2.4	223
47	Convergent Transcription at Intragenic Super-Enhancers Targets AID-Initiated Genomic Instability. Cell, 2014, 159, 1538-1548.	13.5	221
48	PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains. Cancer Research, 2013, 73, 3336-3346.	0.4	218
49	Ligand-Promoted Meta-Câ€“H Arylation of Anilines, Phenols, and Heterocycles. Journal of the American Chemical Society, 2016, 138, 9269-9276.	6.6	216
50	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	9.4	214
51	BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle, 2013, 12, 452-462.	1.3	209
52	Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. Angewandte Chemie - International Edition, 2017, 56, 5738-5743.	7.2	207
53	ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature, 2017, 543, 265-269.	13.7	203
54	BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Science Translational Medicine, 2017, 9, .	5.8	203

#	Article	IF	Citations
55	DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nature Medicine, 2015, 21, 335-343.	15.2	200
56	Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell, 2018, 33, 29-43.e7.	7.7	186
57	Therapeutic Strategies to Inhibit MYC. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a014266-a014266.	2.9	180
58	An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nature Medicine, 2016, 22, 632-640.	15.2	176
59	Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nature Chemical Biology, 2018, 14, 405-412.	3.9	176
60	Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nature Communications, 2018, 9, 53.	5.8	175
61	Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discovery, 2016, 6, 1166-1181.	7.7	171
62	Genome-wide localization of small molecules. Nature Biotechnology, 2014, 32, 92-96.	9.4	165
63	Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nature Genetics, 2018, 50, 515-523.	9.4	163
64	An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Research, 2014, 24, 809-819.	5.7	155
65	MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene, 2014, 33, 1736-1742.	2.6	155
66	BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. Journal of Molecular and Cellular Cardiology, 2013, 63, 175-179.	0.9	154
67	AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes. Cancer Cell, 2014, 26, 896-908.	7.7	153
68	Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer, 2016, 122, 3632-3640.	2.0	145
69	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. Journal of Experimental Medicine, 2015, 212, 1819-1832.	4.2	137
70	An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 232-237.	3.3	136
71	Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Research, 2015, 43, 5880-5897.	6.5	136
72	Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Nonâ€“Small Cell Lung Cancer. Cancer Discovery, 2017, 7, 852-867.	7.7	132

#	Article	IF	Citations
73	Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nature Communications, 2020, 11, 4687.	5.8	129
74	Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders. ACS Chemical Biology, 2018, 13, 553-560.	1.6	128
75	Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood, 2015, 125, 2530-2543.	0.6	125
76	Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. ELife, 2018, 7, .	2.8	125
77	BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD. Molecular Cancer Therapeutics, 2014, 13, 2315-2327.	1.9	123
78	Chromatin proteomic profiling reveals novel proteins associated with histone-marked genomic regions. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3841-3846.	3.3	123
79	Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Nature Communications, 2014, 5, 3511.	5.8	121
80	Small-molecule targeting of brachyury transcription factor addiction in chordoma. Nature Medicine, 2019, 25, 292-300.	15.2	120
81	Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2015, 21, 113-122.	3.2	119
82	Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nature Genetics, 2014, 46, 618-623.	9.4	117
83	CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. Journal of Clinical Investigation, 2017, 128, 446-462.	3.9	117
84	Design and characterization of bivalent BET inhibitors. Nature Chemical Biology, 2016, 12, 1089-1096.	3.9	115
85	BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Research, 2016, 76, 6320-6330.	0.4	115
86	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Molecular Cell, 2020, 78, 1096-1113.e8.	4.5	114
87	Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13162-13167.	3.3	112
88	Synthetic transcription elongation factors license transcription across repressive chromatin. Science, 2017, 358, 1617-1622.	6.0	110
89	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nature Communications, 2019, 10, 4358.	5.8	109
90	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. Cancer Discovery, 2016, 6, 1006-1021.	7.7	108

#	Article	IF	Citations
91	Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell, 2018, 34, 982-995.e7.	7.7	101
92	The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Clinical Cancer Research, 2016, 22, 2534-2544.	3.2	100
93	Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nature Communications, 2017, 8, 14400.	5.8	93
94	Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood, 2015, 126, 1565-1574.	0.6	92
95	PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Reports, 2016, 15, 2692-2704.	2.9	92
96	Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5086-E5095.	3.3	87
97	MELK is not necessary for the proliferation of basal-like breast cancer cells. ELife, 2017, 6, .	2.8	86
98	Selective Mediator dependence of cell-type-specifying transcription. Nature Genetics, 2020, 52, 719-727.	9.4	84
99	Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis. PLoS Pathogens, 2017, 13, e1006668.	2.1	84
100	Biased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 9019-9027.	2.9	80
101	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. Cancer Discovery, 2016, 6, 986-1005.	7.7	79
102	A chemical probe toolbox for dissecting the cancer epigenome. Nature Reviews Cancer, 2017, 17, 160-183.	12.8	76
103	The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. EBioMedicine, 2019, 44, 419-430.	2.7	76
104	Chronic Myelogenous Leukemiaâ€“ Initiating Cells Require Polycomb Group Protein EZH2. Cancer Discovery, 2016, 6, 1237-1247.	7.7	72
105	Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. Oncogene, 2018, 37, 2850-2862.	2.6	71
106	Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA. Cell Reports, 2016, 16, 1366-1378.	2.9	70
107	High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. Cell Reports, 2016, 16, 2003-2016.	2.9	69
108	Gene expression profiling of patientâ€derived pancreatic cancer xenografts predicts sensitivity to the <scp>BET</scp> bromodomain inhibitor <scp>JQ</scp> 1: implications for individualized medicine efforts. EMBO Molecular Medicine, 2017, 9, 482-497.	3.3	66

#	Article	IF	Citations
109	BET bromodomain proteins regulate enhancer function during adipogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2144-2149.	3.3	65
110	Notch inhibition allows oncogene-independent generation of iPS cells. Nature Chemical Biology, 2014, 10, 632-639.	3.9	64
111	MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. Nature Genetics, 2019, 51, 990-998.	9.4	61
112	The use of small molecules in somatic-cell reprogramming. Trends in Cell Biology, 2014, 24, 179-187.	3.6	60
113	Relative Binding Free Energy Calculations Applied to Protein Homology Models. Journal of Chemical Information and Modeling, 2016, 56, 2388-2400.	2.5	60
114	Development of a Potent and Selective HDAC8 Inhibitor. ACS Medicinal Chemistry Letters, 2016, 7, 929-932.	1.3	59
115	The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation. Journal of Cellular Physiology, 2015, 230, 2683-2694.	2.0	58
116	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Molecular Cancer Therapeutics, 2016, 15, 2030-2041.	1.9	57
117	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Reports, 2021, 34, 108532.	2.9	54
118	Activation of SOX2 Expression by BRD4-NUT Oncogenic Fusion Drives Neoplastic Transformation in NUT Midline Carcinoma. Cancer Research, 2014, 74, 3332-3343.	0.4	53
119	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Science Translational Medicine, 2017, 9, .	5.8	53
120	Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends in Immunology, 2012, 33, 563-570.	2.9	52
121	Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD. Human Molecular Genetics, 2015, 24, 3982-3993.	1.4	51
122	Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. Bone, 2017, 94, 10-21.	1.4	51
123	Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells. PLoS ONE, 2014, 9, e87003.	1.1	51
124	PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma. Nature Communications, 2019, 10, 3739.	5.8	49
125	Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases. Journal of Biological Chemistry, 2016, 291, 23756-23768.	1.6	48
126	Eradication of Acute Myeloid Leukemia with FLT3 Ligandâ€“Targeted miR-150 Nanoparticles. Cancer Research, 2016, 76, 4470-4480.	0.4	48

#	Article	IF	Citations
127	Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia. Cancer Research, 2014, 74, 7048-7059.	0.4	46
128	Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 7785-7795.	2.9	46
129	MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica, 2015, 100, e190-e193.	1.7	45
130	A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. Frontiers in Microbiology, 2017, 8, 1035.	1.5	45
131	Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. ACS Chemical Biology, 2018, 13, 2438-2448.	1.6	44
132	Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1. Oncotarget, 2016, 7, 24125-24140.	0.8	42
133	Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. Blood, 2018, 131, 771-781.	0.6	42
134	BET and BRAF inhibitors act synergistically against BRAFâ€•mutant melanoma. Cancer Medicine, 2016, 5, 1183-1193.	1.3	41
135	In Vivo Pharmacodynamic Imaging of Proteasome Inhibition. Molecular Imaging, 2009, 8, 7290.2009.00007.	0.7	40
136	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. Journal of Clinical Investigation, 2020, 130, 5875-5892.	3.9	40
137	BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen. Journal of Medicinal Chemistry, 2017, 60, 4805-4817.	2.9	39
138	NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model. Cancer Research, 2018, 78, 3709-3717.	0.4	38
139	Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. Science Advances, 2021, 7, .	4.7	38
140	Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape. Cell Reports, 2015, 12, 1300-1313.	2.9	37
141	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nature Communications, 2019, 10, 2400.	5.8	37
142	Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010â€“2014). Pharmaceutical Patent Analyst, 2015, 4, 261-284.	0.4	36
143	HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Science Translational Medicine, 2017, 9, .	5.8	36
144	Tubacin Kills Epstein-Barr Virus (EBV)-Burkitt Lymphoma Cells by Inducing Reactive Oxygen Species and EBV Lymphoblastoid Cells by Inducing Apoptosis. Journal of Biological Chemistry, 2009, 284, 17102-17109.	1.6	34

#	Article	IF	Citations
145	Transcriptional and post-transcriptional control of adipocyte differentiation by Jumonji domain-containing protein 6. Nucleic Acids Research, 2015, 43, 7790-7804.	6.5	33
146	Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole. Bioorganic and Medicinal Chemistry, 2015, 23, 5061-5074.	1.4	32
147	Leukemia-specific delivery of mutant NOTCH1 targeted therapy. Journal of Experimental Medicine, 2018, 215, 197-216.	4.2	30
148	Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer. Oncotarget, 2016, 7, 72395-72414.	0.8	30
149	Pojamide: An HDAC3-Selective Ferrocene Analogue with Remarkably Enhanced Redox-Triggered Ferrocenium Activity in Cells. Organometallics, 2017, 36, 3276-3283.	1.1	28
150	JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma. Molecular Cancer Therapeutics, 2018, 17, 107-118.	1.9	27
151	Targeting oncoproteins with a positive selection assay for protein degraders. Science Advances, 2021, 7, .	4.7	26
152	Identification of ATRâ€“Chk1 Pathway Inhibitors That Selectively Target p53-Deficient Cells without Directly Suppressing ATR Catalytic Activity. Cancer Research, 2014, 74, 7534-7545.	0.4	25
153	An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. Cell Chemical Biology, 2021, 28, 802-812.e6.	2.5	25
154	Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. Cell Reports, 2018, 25, 3693-3705.e6.	2.9	23
155	BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy. JCI Insight, 2020, 5, .	2.3	23
156	Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	22
157	A Beadâ€Based Proximity Assay for BRD4 Ligand Discovery. Current Protocols in Chemical Biology, 2015, 7, 263-278.	1.7	21
158	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood, 2019, 133, 94-99.	0.6	21
159	Evolutionary conserved NSL complex/BRD4 axis controls transcription activation via histone acetylation. Nature Communications, 2020, 11, 2243.	5.8	21
160	Structure-Guided DOT1L Probe Optimization by Label-Free Ligand Displacement. ACS Chemical Biology, 2015, 10, 667-674.	1.6	20
161	Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5746-E5755.	3.3	20
162	An essential passenger with p53. Nature, 2015, 520, 626-627.	13.7	19

#	Article	IF	Citations
163	Assessment of Bromodomain Target Engagement by a Series of BI2536 Analogues with Miniaturized BET-BRET. ChemMedChem, 2016, 11, 2575-2581.	1.6	17
164	Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Research, 2019, 79, 994-1009.	0.4	17
165	Epigenetic Reprogramming of Lineage-Committed Human Mammary Epithelial Cells Requires DNMT3A and Loss of DOT1L. Stem Cell Reports, 2017, 9, 943-955.	2.3	16
166	Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4 ⁺ T cells ex vivo. Science Advances, 2020, 6, eaba1941.	4.7	16
167	Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. Angewandte Chemie, 2017, 129, 5832-5837.	1.6	14
168	Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold. ACS Medicinal Chemistry Letters, 2019, 10, 1443-1449.	1.3	11
169	A novel Î²-catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer. Science Advances, 2022, 8, eabm3108.	4.7	10
170	The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia, 2021, 23, 624-633.	2.3	8
171	Maintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465). Experimental Hematology, 2019, 75, 53-63.e11.	0.2	5
172	Treatment with Histone Deacetylase 6-Specific Inhibitor WT-161 Disrupts hsp90 Function, Abrogates Aggresome Formation and Sensitizes Human Mantle Cell Lymphoma Cells to Lethal ER Stress Induced by Proteasome Inhibitor Carfilzomib. Blood, 2010, 116, 2856-2856.	0.6	5
173	Selective targeting of MYC mRNA by stabilized antisense oligonucleotides. Oncogene, 2021, 40, 6527-6539.	2.6	5
174	Genome-Wide RNAi Screen Identifies The Mechanistic Role For DOT1L In MLL-Rearranged Leukemia. Blood, 2013, 122, 598-598.	0.6	4
175	7,9-Diaryl-1,6,8-trioxaspiro[4.5]dec-3-en-2-ones: Readily accessible and highly potent anticancer compounds. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4035-4038.	1.0	3
176	Synthesis and Biochemical Evaluation of Biotinylated Conjugates of Largazole Analogues: Selective Class I Histone Deacetylase Inhibitors. Israel Journal of Chemistry, 2017, 57, 319-330.	1.0	3
177	Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma. Blood, 2011, 118, 1869-1869.	0.6	3
178	SALL4 Is a Key Factor in HDAC Inhibitor Mediated Ex Vivo Expansion of Human Peripheral Blood Mobilized Stem/Progenitor CD34+CD90+ Cells. Blood, 2014, 124, 1566-1566.	0.6	3
179	Enhancer Landscapes Reveal Transcription Factor Network Dependencies in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 436-436.	0.6	3
180	JQ1, a Selective Bromodomain Inhibitor, Augment the Immunogenicity of Mantle Cell Lymphoma By Influencing the Expression of PD-L1. Blood, 2015, 126, 822-822.	0.6	3

#	Article	IF	Citations
181	Induction of Human Fetal Hemoglobin Expression by Selective Inhibitors of Histone Deacetylase 1 and 2 (HDAC1/2). Blood, 2012, 120, 3259-3259.	0.6	3
182	A Soft-Drug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma.. Blood, 2007, 110, 800-800.	0.6	2
183	Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM). Blood, 2010, 116, 2997-2997.	0.6	2
184	Phenothiazines Induce Apoptosis in T-Cell Acute Lymphoblastic Leukemia by Activating the Phosphatase Activity of the PP2A Tumor Suppressor. Blood, 2012, 120, 3558-3558.	0.6	2
185	Ongoing Spontaneous DNA Damage and the Role of Aberrant Epigenome in Multiple Myeloma. Blood, 2014, 124, 3398-3398.	0.6	2
186	Targeted Treatment of FLT3 -Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides. Blood, 2015, 126, 3784-3784.	0.6	2
187	Genome-Wide Mapping Reveals BRD4 in Regulation of Tumor-Driver Genes in Cutaneous T-Cell Lymphoma. Blood, 2015, 126, 589-589.	0.6	2
188	A pulse at the heart of targeted therapy. Nature Chemical Biology, 2009, 5, 144-145.	3.9	1
189	From transcriptional regulation to drugging the cancer epigenome. Genome Medicine, 2014, 6, 123.	3.6	1
190	Tag and Capture Flow Hydrogen Exchange Mass Spectrometry with a Fluorous-Immobilized Probe. Analytical Chemistry, 2015, 87, 6349-6356.	3.2	1
191	High Throughput Screening Identifies Potential Inhibitors of WHSC1/MMSET, a Histone Methyltransferase Oncoprotein in Multiple Myeloma and Acute Lymphocytic Leukemia. Blood, 2015, 126, 3251-3251.	0.6	1
192	Targeting STAT5 in Leukemia Through Inhibition of Bromodomain Proteins. Blood, 2012, 120, 399-399.	0.6	1
193	Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells. Blood, 2013, 122, 2842-2842.	0.6	1
194	Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells. Blood, 2014, 124, 918-918.	0.6	1
195	Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis. Blood, 2015, 126, 435-435.	0.6	1
196	Discovery and Characterization of Promoter and Super-Enhancer-Associated Dependencies through E2F and BET Bromodomains in Multiple Myeloma. Blood, 2015, 126, 838-838.	0.6	1
197	Targeting the Protein Degradation Pathway in Multiple Myeloma with Synergistic, Selective Small Molecules.. Blood, 2005, 106, 2471-2471.	0.6	0
198	Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells.. Blood, 2006, 108, 3426-3426.	0.6	0

#	Article	IF	Citations
199	Targeting Histone Deacetylase 6 and the Aggresome Pathway in Acute Lymphoblastic Leukemia Cells.. Blood, 2007, 110, 1602-1602.	0.6	0
200	Discovery and Characterization of Macrocyclic Thiopeptide Proteasome Inhibitors for Hematologic Malignancies. Blood, 2008, 112, 3669-3669.	0.6	0
201	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. Blood, 2011, 118, 1409-1409.	0.6	0
202	Induction of Fetal Hemoglobin by Inactivation of HDAC1 or HDAC2 without Altering Cellular Proliferation. Blood, 2011, 118, 354-354.	0.6	0
203	Silencing c-Myc Using Myc Inhibitor JQ1 and EZH2 Inhibitor DZNep Blocks Converging Survival Signals in Aggressive B-Cell Lymphomas. Blood, 2012, 120, 4618-4618.	0.6	0
204	The Interaction Between DOT1L and AF10 Is Required for H3K79 Dimethylation and MLL-AF9 Leukemia. Blood, 2012, 120, 401-401.	0.6	0
205	Targeting Bromodomains in Myeloma. Blood, 2012, 120, SCI-6-SCI-6.	0.6	0
206	Disruption of the Ikaros-Mediated Gene Expression Program in Multiple Myeloma with Immunomodulatory Agents. Blood, 2014, 124, 420-420.	0.6	0
207	Structure-Guided Design of DOT1L Methyltransferase Inhibitors By a Novel, Label Free Assay Platform. Blood, 2014, 124, 4811-4811.	0.6	0
208	Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells. Blood, 2014, 124, 3534-3534.	0.6	0
209	Structural Dynamics of the NSD Family Histone Methyltransferases. FASEB Journal, 2015, 29, 717.13.	0.2	0
210	Abstract A41: Shaping Myc-dependent transcriptional amplification. , 2015, , .		0
211	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. Journal of Cell Biology, 2015, 211, 2111OIA226.	2.3	0